|Table of Contents|
Immunomodulatory antibodies for therapy of cancer
It has been known for many years that immunological mechanisms play a key role in cancers, including those which are most common in humans. However, for several decades, the benefit of active immunotherapy was modest. This situation is now rapidly changing. In particular, systemic administration of immunomodulatory monoclonal antibodies (mAbs) has demonstrated clinical efficacy, including complete remission in several patients treated at tolerable toxicity for melanoma or other particular types of tumours.6,7 These findings are remarkable but much remains to be learned.